2 Coronavirus Treatment Stocks to Buy Right Now
Companies attempting to develop effective coronavirus vaccines have taken center stage on Wall Street in 2020. Pfizer, Novavax, Vaxart, and others have all seen their share prices scream higher because of their COVID-19 programs.
The core reason is that the federal government's Operation Warp Speed has plowed approximately $11 billion into the development of vaccine candidates on accelerated timelines. The cold, hard truth, though, is that a vaccine alone will not be a panacea for this particular virus.
Source Fool.com